62 - Safety and Efficacy of Percutaneous Image-Guided Ablation in Breast Cancer Metastases to the Liver

Monday, March 31, 2025

12:10 PM – 1:10 PM CT

Location: Music City Center, Expo Poster Area

Poster Presenter(s)

Govindarajan Narayanan, MD, FSIR

Professor and Interventional Radiologist
Miami Cardiac & Vascular Institute, United States

Author/Co-author(s)

BV

Bente Van Den Bemd, MD

Research associate
Miami cancer institute, United States
Ripal Gandhi, MD, FSIR

Interventional Radiologist
Miami Cardiac & Vascular Institute, Miami Cancer Institute, United States
MD

Madelon Dijkstra, MD

Research associate
Miami cancer institute, United States
DD

Danielle Donahue, MD

Research/ medical student
Miami cancer institute, United States

Purpose: This is a single-center retrospective study to evaluate safety, efficacy, and overall survival (OS), of breast cancer patients with liver metastases (BCLM), treated with percutaneous ablation using microwave (MW) irreversible electroporation (IRE), and cryoablation.

Materials and Methods: Between August 2018 and December 2023, 32 patients underwent 40 treatments of image-guided percutaneous ablation under general anesthesia for BCLM. Mean age was 61.3 years at time of treatment (range: 32-85) and mean size of treated lesions was 2.6 cm (range: 0.5-7 cm). Fifty lesions were treated with MWA, 5 with IRE, and 2 with cryoablation. Efficacy was determined by treatment response, using mRECIST, at first follow-up imaging and by local tumor progression (LTP) during total follow-up time. Complications, using CTCAE grading, were recorded to assess safety. Kaplan-Meier statistics were used to evaluate LTP and OS.

Results: First follow-up showed complete response in 34 tumors (59.6%), partial response in 14 (24.6%), and progressive disease in 9 (15.8%). LTP was noted in 37 tumors (64.9%) and median time to LTP was 11.1 months (95% CI 1.4-20.8). There were twelve Grade 1 complications, three Grade 2 and one Grade 3 (hemodynamic instability) that required an angiogram, without intervention. Sixteen of the 32 patients died during follow-up and median OS from ablation was 27.8 months (95% CI 19.0-36.6).

Conclusion: Percutaneous ablation is a safe and viable option in BCLM patients progressing on systemic therapy, and median OS reached comparable results to current literature. Future studies should further assess the additive value of ablation in BCLM.